Alpha-galactosylceramide as mRNA vaccine adjuvant modulates cellular immunity against tuberculosis and contributes to antigen-specific lung-associated T cells with a TRM-associated phenotype following prime-pull strategy

Ilke Aernout, Thomas Ehouarne, Kevin Mwangi, Kia C. Ferrell, Margo De Velder, Janne Swinnen, Aaron Verplancke, Laura Van Moortel, Margaux De Meyer, Patrick Willems, Lorenzo Franceschini, Karine Breckpot, Stefaan C. De Smedt, Francis Impens, Caroline Demangel, Rein Verbeke, Ine Lentacker

Open source

DOI: 10.3389/fimmu.2026.1929726
Published: 2026-10-05
Container: Frontiers in Immunology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1929726,
  title = {Alpha-galactosylceramide as mRNA vaccine adjuvant modulates cellular immunity against tuberculosis and contributes to antigen-specific lung-associated T cells with a TRM-associated phenotype following prime-pull strategy},
  author = {Ilke Aernout and Thomas Ehouarne and Kevin Mwangi and Kia C. Ferrell and Margo De Velder and Janne Swinnen and Aaron Verplancke and Laura Van Moortel and Margaux De Meyer and Patrick Willems and Lorenzo Franceschini and Karine Breckpot and Stefaan C. De Smedt and Francis Impens and Caroline Demangel and Rein Verbeke and Ine Lentacker},
  year = {2026},
  journal = {Frontiers in Immunology},
  doi = {10.3389/fimmu.2026.1929726},
  url = {https://doi.org/10.3389/fimmu.2026.1929726}
}

RIS

TY  - JOUR
TI  - Alpha-galactosylceramide as mRNA vaccine adjuvant modulates cellular immunity against tuberculosis and contributes to antigen-specific lung-associated T cells with a TRM-associated phenotype following prime-pull strategy
AU  - Ilke Aernout
AU  - Thomas Ehouarne
AU  - Kevin Mwangi
AU  - Kia C. Ferrell
AU  - Margo De Velder
AU  - Janne Swinnen
AU  - Aaron Verplancke
AU  - Laura Van Moortel
AU  - Margaux De Meyer
AU  - Patrick Willems
AU  - Lorenzo Franceschini
AU  - Karine Breckpot
AU  - Stefaan C. De Smedt
AU  - Francis Impens
AU  - Caroline Demangel
AU  - Rein Verbeke
AU  - Ine Lentacker
PY  - 2026
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1929726
UR  - https://doi.org/10.3389/fimmu.2026.1929726
ER  -

APA

Aernout, I., Ehouarne, T., Mwangi, K., Ferrell, K. C., Velder, M. D., Swinnen, J., Verplancke, A., Moortel, L. V., Meyer, M. D., Willems, P., Franceschini, L., Breckpot, K., Smedt, S. C. D., Impens, F., Demangel, C., Verbeke, R., & Lentacker, I. (2026). Alpha-galactosylceramide as mRNA vaccine adjuvant modulates cellular immunity against tuberculosis and contributes to antigen-specific lung-associated T cells with a TRM-associated phenotype following prime-pull strategy. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1929726

Source records

crossref · retrieved 2026-11-10T20:18:11.294Z